Entity

Time filter

Source Type


Chen R.,Nanjing Medical University | Lu M.,Nanjing Medical University | Wang J.,Jiangsu Provincial Hospital | Zhang D.,Nanjing Medical University | And 9 more authors.
Virchows Archiv | Year: 2013

Human trophoblastic cell surface antigen 2 (Trop2) has been suggested to play an important role in the development of solid tumors. However, the expression of Trop2 in extranodal NK/T cell lymphoma, nasal type (ENKTL) and the relationship with the clinical characteristics of this disease remain poorly understood. In this study, one-step quantitative PCR reverse transcription-polymerase chain reaction and immunohistochemical staining with tissue sections were employed to evaluate the expression of Trop2 in ENKTL. Furthermore, the relationship between Trop2 expression and prognosis of ENKTL was investigated. Expression of Trop2 mRNA and protein was significantly higher in ENKTL tissue than in corresponding non-lymphomatous tissue (p = 0.04 and p < 0.001, respectively). Expression of Trop2 protein in ENKTL was associated with lymph node involvement and poor overall survival (p = 0.045 and p = 0.018, respectively). Kaplan-Meier analysis and the logrank test indicated that lymph node involvement (p = 0.0481), single therapy strategy (p = 0.0037), and high expression of Trop2 (p = 0.0042) are significantly correlated with poor prognosis of ENKTL patients. The data suggest that Trop2 expression reflects a more malignant phenotype and may serve as an unfavorable prognostic factor for ENKTL. © 2013 Springer-Verlag Berlin Heidelberg. Source


Lin H.,Huadong Medical Institute of Biotechniques | Lin H.,Nanjing Medical University | Lin H.,Jiangsu Provincial Blood Center | Zhang H.,Nanjing Medical University | And 13 more authors.
International Journal of Cancer | Year: 2014

Human trophoblastic cell surface antigen 2 (Trop2) has been suggested as an oncogene, which is associated with the different types of tumors. In this study, a human Fab antibody against Trop2 extracellular domain was isolated from phage library by phage display technology, and characterized by ELISA, FACS, fluorescence staining and Western blotting analysis. MTT, apoptosis assay and wound healing assay were employed to evaluate the inhibitory effects of Trop2 Fab on breast cancer cell growth in vitro, while tumor-xenograft model was employed to evaluate the inhibitory effects on breast cancer growth in vivo. The results showed that Trop2 Fab inhibited the proliferation, induced the apoptosis and suspended the migration of MDA-MB-231 cells in a dose dependent manner. The expression caspase-3 was activated, and the expression of Bcl-2 was reduced while that of Bax was elevated in MDA-MB-231 cells by treating with Trop2 Fab. In addition, Trop2 Fab inhibited the growth of breast cancer xenografts and the expression of Bcl-2 was reduced while that of Bax was elevated in xenografts. Trop2 Fab, which was isolated successfully in this research, is a promising therapeutic agent for the treatment of Trop2 expressing breast cancer. © 2013 UICC. Source


Lin H.,Jiangsu Provincial Blood Center | Mao Y.,Jiangsu Province Official Hospital | Zhang D.-W.,Nanjing Medical University | Li H.,Nanjing Medical University | And 4 more authors.
Anti-Cancer Agents in Medicinal Chemistry | Year: 2013

Melanoma-associated antigen (MAGE) is expressed on the surface of multiple tumor cell types and is a promising target of biotherapeutic drug delivery via the anti-MAGE-A1 antibody. In this study, a human single-chain variable fragment (scFv) antibody phage library was generated and applied to recombinant MAGE-A1-coated immunotubes by phage display technology. The soluble antiMAGE-A1 scFv was expressed and purified by immobilized metal-chelated affinity chromatography (IMAC). The anti-MAGE-A1 scFv could bind native MAGE-A1 confirmed by enzyme-linked immunosorbent assay (ELISA), dot blot, and immunoprecipitation (IP) analysis. The immunotoxin was expressed and purified by IMAC successfully. The results indicated that the human anti-MAGE-A1 immunotoxin could provide a valuable drug for clinic cancer therapy. © 2013 Bentham Science Publishers. Source


Mao Y.,Jiangsu Province Official Hospital | Mao Y.,Huadong Medical Institute of Biotechnology | Lu M.P.,Nanjing Medical University | Lin H.,Jiangsu Provincial Blood Center | And 7 more authors.
PLoS ONE | Year: 2013

Background: Epstein-Barr virus (EBV) infection has been associated with lymphoma development. EBV latent membrane protein 1 (LMP1) is essential for EBV-mediated transformation and progression of different human cells, including lymphocytes. This meta-analysis investigated LMP1 expression with prognosis of patients with lymphoma. Methods: The electronic databases of PubMed, Embase, and Chinese Biomedicine Databases were searched. There were 15 published studies available for a random effects model analysis. Quality assessment was performed using the Newcastle-Ottawa Quality Assessment Scale for cohort studies. A funnel plot was used to investigate publication bias, and sources of heterogeneity were identified by meta-regression analysis. The combined hazard ratios (HR) and their corresponding 95% confidence intervals of LMP1 expression were calculated by comparison to the overall survival. Results: Overall, there was no statistical significance found between LMP1 expression and survival of lymphoma patients (HR 1.25 [95% CI, 0.92-1.68]). In subgroup analyses, LMP1 expression was associated with survival in patients with non-Hodgkin lymphoma (NHL) (HR = 1.84, 95% CI: 1.02-3.34), but not with survival of patients with Hodgkin disease (HD) (HR = 1.03, 95% CI: 0.74-1.44). In addition, significant heterogeneity was present and the meta-regression revealed that the outcome of analysis was mainly influenced by the cutoff value. Conclusions: This meta-analysis demonstrated that LMP1 expression appears to be an unfavorable prognostic factor for overall survival of NHL patients. The data suggested that EBV infection and LMP1 expression may be an important factor for NHL development or progression. © 2013 Mao et al. Source


Xue M.,Jiangsu Provincial Blood Center
Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology | Year: 2012

The purpose of this study was to investigate the allele frequencies of the human platelet alloantigens 1-18 system (HPA-1-18) in Chinese Nanjing unrelated and healthy Han population, so as to provide the credible basis to screen compatible platelets for transfusing patients. The genotypes of 18 HPA systems were determined by polymerase chain reaction using sequence-specific primer (PCR-SSP) for 300 samples. The results showed that the gene frequencies obtained from 300 Nanjing unrelated population were 0.9183 and 0.0817 for HPA-2a and -2b, 0.6100 and 0.3900 for HPA-3a and -3b, 0.9733 and 0.0267 for HPA-5a and -5b, 0.9883 and 0.0117 for HPA-6a and -6b, 0.5250 and 0.4750 for HPA-15a and -15b. All the tested individuals were homozygotes for HPA-1a, -4a, -7a-14a and HPA -16a-18a. There was a good fit to Hardy-Weinberg equilibrium in each group. It is concluded that this study has confirmed the ethnic and regional difference of HPA, and HPA in Nanjing Han population has its own characteristics. The highest heterozygotes are HPA-3 and HPA-15, thus more attention to HPA effects on clinical platelet matched transfusion should be paid. Source

Discover hidden collaborations